Emisphere Technologies, Inc.
Mar 21, 2017

Emisphere Announces Fourth Quarter and Full Year 2016 Earnings Conference Call

Conference Call/Webcast to be Held Wednesday, March 29, 2017, at 8:30 AM ET

ROSELAND, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2016, on Wednesday, March 29, 2017, at 8:30 AM ET. A press release will be issued prior to market open.

The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com.  The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 90730730.

In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Wednesday, March 29, 2017 at 11:30 AM ET through 11:30 AM ET on April 05, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 90730730.

About Emisphere

Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12.  Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions.  Our capabilities range from early proof of concept, to extensive development and commercial capabilities.

Emisphere's technology can enhance the clinical profile of both pre-market and currently marketed products.  Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties.  Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.

CONTACT:



Alan L. Rubino, CEO

973.532.8000

arubino@emisphere.com

Primary Logo

Source: Emisphere Technologies, Inc.

News Provided by Acquire Media